TCI Wealth Advisors’s Immunovant IMVT Stock Holding History

TCI Wealth Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-226	Closed	-$3.51K	–	1160
2023 Q1	$3.51K	Buy	+226	New	+$3.92K	﹤0.01%	1763

Other funds holding IMVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

TCI Wealth Advisors's IMVT Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Immunovant (IMVT) in Q2 2023, closing a stake of 226 shares — an estimated $3.51K sold.

TCI Wealth Advisors first reported a position in IMVT in Q1 2023 and held it in 1 quarter. The position peaked at $3.51K in Q1 2023. 147 funds tracked by Wall St. Rank hold IMVT as of Q2 2023.

TCI Wealth Advisors reported no remaining Immunovant position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 226 Immunovant shares in Q2 2023, an estimated $3.51K.
TCI Wealth Advisors first reported a position in Immunovant in Q1 2023 and held it in 1 quarter.
TCI Wealth Advisors's Immunovant position peaked at $3.51K in Q1 2023.
147 funds tracked by Wall St. Rank held Immunovant as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.